A detailed history of Two Sigma Securities, LLC transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Securities, LLC holds 3,400 shares of ALNY stock, worth $839,120. This represents 0.02% of its overall portfolio holdings.

Number of Shares
3,400
Previous 54,142 93.72%
Holding current value
$839,120
Previous $13.2 Million 92.89%
% of portfolio
0.02%
Previous 0.16%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$143.31 - $247.0 $7.76 Million - $13.4 Million
54,142 New
54,142 $13.2 Million
Q2 2023

Aug 14, 2023

BUY
$185.01 - $212.05 $664,185 - $761,259
3,590 Added 236.03%
5,111 $970,000
Q1 2023

May 15, 2023

SELL
$182.66 - $235.53 $450,622 - $581,052
-2,467 Reduced 61.86%
1,521 $304,000
Q4 2022

Feb 14, 2023

BUY
$185.53 - $241.31 $163,451 - $212,594
881 Added 28.36%
3,988 $947,000
Q3 2022

Nov 14, 2022

SELL
$138.54 - $232.0 $1.13 Million - $1.9 Million
-8,183 Reduced 72.48%
3,107 $622,000
Q2 2022

Aug 15, 2022

BUY
$120.42 - $169.29 $455,428 - $640,254
3,782 Added 50.37%
11,290 $1.65 Million
Q1 2022

May 16, 2022

BUY
$127.18 - $173.91 $684,609 - $936,157
5,383 Added 253.32%
7,508 $1.23 Million
Q4 2021

Feb 14, 2022

BUY
$159.56 - $209.29 $339,065 - $444,741
2,125 New
2,125 $360,000
Q3 2021

Nov 15, 2021

SELL
$169.75 - $207.73 $350,703 - $429,170
-2,066 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$128.63 - $176.89 $43,476 - $59,788
-338 Reduced 14.06%
2,066 $350,000
Q4 2019

Feb 14, 2020

SELL
$74.51 - $124.23 $8,941 - $14,907
-120 Reduced 4.75%
2,404 $277,000
Q1 2018

May 15, 2018

BUY
$115.92 - $148.54 $56,221 - $72,041
485 Added 23.79%
2,524 $301,000
Q3 2017

Nov 14, 2017

BUY
$72.53 - $118.27 $147,888 - $241,152
2,039
2,039 $240,000

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $30.4B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Two Sigma Securities, LLC Portfolio

Follow Two Sigma Securities, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Securities, LLC with notifications on news.